LABORATORY CORPORATION OF AMERICA HOLDINGS

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Report language accompanying H.R. 8646, the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027, provisions relating to oversight of laboratory-developed tests.